Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
The treatment of adductor spasmodic dysphonia using botulinum toxin A was conducted in 13 patients as a double-blind, placebo-controlled study. Patients were diagnosed independently by an interdisciplinary team consisting of speech pathologists, an otolaryngologist, and a neurologist. The toxin or saline was injected into each thyroarytenoid muscle under electromyographic and laryngoscopic guidance. Botulinum toxin A markedly reduced perturbation, decreased fundamental frequency range, and improved the spectrographic characteristics of the voice. Fundamental frequency and phonation time remained unchanged. Patients injected with botulinum toxin A noticed significant improvement in their voices in comparison with the placebo-treated group. Excessive breathiness of the voice occurred in two patients, and mild bleeding in one patient in the botulinum toxin A-treated group. Injection with saline resulted in edema of the vocal cord in one patient. Botulinum toxin A proved to be an effective and safe treatment of adductor spasmodic dysphonia.
Troung
D D
DD
Department of Neurology, University of California, Irvine Medical Center, Orange 92668.
Rontal
M
M
Rolnick
M
M
Aronson
A E
AE
Mistura
K
K
D001905:Botulinum Toxins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D007273:Injections, Intramuscular; D007821:Laryngeal Muscles; D013018:Sound Spectrography; D013035:Spasm / Q000188:drug therapy; D013060:Speech / Q000502:physiology; D014832:Voice Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
D001905:Botulinum Toxins